5 Topic Commentaries

FDA clears pTau217 blood test for Alzheimer's disease

• 

  Abhay R. Moghekar, MBBS

  Neurology

  •

  Johns Hopkins University School of Medicine

  It makes things much easier for both patients and physicians. New medications are now available to treat Alzheimer’s disease, but they are only effective if it is diagnosed early, and early diagnosis depends on having accurate biomarkers.

  Source
• 

  Sanjay Asthana, MD

  Geriatrics

  •

  University of Wisconsin–Madison

  This is spectacular news and a breakthrough in identifying reliable blood biomarkers for Alzheimer’s disease.

  Source
• 

  Sterling Johnson, PhD

  Neuroscience

  •

  University of Wisconsin–Madison

  This milestone transforms years of patient-centered research into a tool physicians can now use to benefit their patients and guide care.

  Source
• 

  Nathaniel Chin, MD

  Geriatric Medicine

  •

  University of Wisconsin School of Medicine and Public Health

  A blood test of this kind is going to greatly expand clinicians’ ability to confirm that Alzheimer’s is present.

  Source
• 

  Michal Schnaider Beeri, PhD

  Neurology

  •

  Rutgers University, Robert Wood Johnson Medical School

  This blood test offers a simpler, less invasive, and more widely accessible way to support accurate detection of amyloid plaques and tau tangles, two of the main pathological markers of Alzheimer’s disease.

  Source